CAR-T cells / Chinese PLA General Hospital - LARVOL DELTA

Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013-2025. (PubMed, Hum Vaccin Immunother) - "The field of research concerning CAR-T cell therapy for multiple myeloma is experiencing rapid advancement. This study systematically summarizes the global research trends, research hotspots and emerging directions in this field, which provides valuable reference for researchers in this field."

Journal • Review • Hematological Malignancies • Multiple Myeloma • Oncology

PHASE I CLINICAL TRIAL OF CD19 CAR -T CELLS SECRETING PD-1-TARGETING IL-21 IN RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (EHA 2026) - P=N/A | "Patients received PZ04 cell infusion following lymphodepleting chemotherapy with an FC regimen (fludarabine/cytarabine). The bispecific CD19-targeted CAR-T cells secreting the PD-1Ab21 fusion entity (PZ04) demonstrate a high response rate and a manageable safety profile in patients with R/R B-ALL. Its innovative design provides a novel strategy to counteract T-cell exhaustion and shows potential as an effective bridge to transplantation. Larger studies are warranted to validate its long-term efficacy."

Clinical • P1 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • IL21 • PD-1

REAL-WORLD OUTCOMES OF ZEVORCABTAGENE AUTOLEUCEL, A FULLY HUMAN BCMA-TARGETED CAR-T THERAPY, IN 136 PATIENTS WITH MULTIPLE MYELOMA (MM): A MULTICENTER EXPERIENCE FROM CHINA (EHA 2026) - P1/2 | "All patients received a single infusion of Zevor-cel at the dose of 1.5×10 8 CAR-T cells/kg...Safety profiles showed predominantly low-grade CRS and an extremely low incidence of ICANS. These results validate Zevor-cel as an effective therapeutic option with a potential superior safety profile, although longer follow-up is required to evaluate survival outcomes and long-term safety profiles."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Leukemia • Multiple Myeloma • Neutropenia • Plasma Cell Leukemia • Thrombocytopenia

PD-1AB21-EXPRESSING, ANTI-CD19 CAR T CELLS FOR PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: AN OPEN-LABEL, SINGLE-ARM, PHASE 1 STUDY (EHA 2026) - "Methods In this open-label, single-arm, phase I trial, patients (aged 14–75 years) with CD19-positive R/R DLBCL received lymphodepletion with fludarabine/cyclophosphamide, followed by a single infusion of PD-1Ab21-CD19 CAR-T cells at doses of 0.3, 1, 3, or 9×10 ⁶ cells/kg. The localized delivery of PD-1 blockade and IL-21 via engineered CAR-T cells may mitigate systemic toxicity while enhancing efficacy. These findings warrant further in ."

CAR T-Cell Therapy • Clinical • P1 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • IL21

FISRT-IN-HUMAN OF ALPACA-DERIVED NANOBODY-BASED BISPECIFIC EPITOPE CD5 CAR-T CELLS FOR RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (EHA 2026) - P1/2 | "Furthermore, we got the safety and efficacy profiles of NbCD5 CAR-T in r/r T-ALL. Our trial is still ongoing, it requires further investigation of long-term efficacy, safety and immune reconstitution."

Bispecific • CAR T-Cell Therapy • Acute Lymphocytic Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • CD5 • CD7 • LAMP1

OPTIMIZED CD33(FL33) CAR-T CELLS IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: A PHASE 1/2CLINICAL TRIAL (EHA 2026) - P1 | "Background Despite our previous optimized CD33 CAR-T therapy(FL33-01, J Pan, et al.Nature Communications, 2024) showed improved anti- leukemia ef-cacy in relapsed/refractory acute myeloid leukemia (r/r AML), grade 4 cytokine release syndrome (CRS) were identi-ed, associated with elevated serum IL-6, IFN- γ , and TNF- α unresponsive to tocilizumab or corticosteroids...Cohorts A/B received standard lymphodepletion (Bu 0.8-1.2mg/kg q6h×1d, VP-16 100mg/m²×1d, Fludarabine 30mg/m²×3d, Cyclophosphamide 250mg/m²×3d); Cohort C received enhanced lymphodepletion (Cyclophosphamide 30mg/kg×3d instead of 250mg/m² 3d)...100% grade 3-4 neutropenia, onocytopenia and thrombocytopenia and obvious serum TNF-a increased (median peak: 62.89pg/ml, range 16.21-271.82), potentially due to CD33-expressing monocyte-macrophage activation, with median recovery 8.5 days after etanercept...Summary/Conclusion Optimized CD33(FL33-02 and FL33-03) CAR-T..."

CAR T-Cell Therapy • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Thrombocytopenia • CD33 • IL6 • TNFA

The TNFR2M196R germline variant confers dual impact on CAR-T cell immunotherapy by enhancing T-cell survival and tumor proliferation. (PubMed, J Genet Genomics) - "The TNFR2M196R variant is found to enhance the antitumor efficacy of CAR-T cells by reducing their apoptosis...Further investigation reveals that while the TNFR2M196R mutation increases tumor susceptibility to CAR-T-mediated killing, it also accelerates tumor proliferation kinetics. Together, these results establish the TNFR2M196R SNP as a dual-function genetic determinant that modulates both CAR-T cell efficacy and intrinsic tumor behavior, highlighting the critical impact of germline genetics on cancer immunotherapy."

IO biomarker • Journal • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

In vivo CD19 CAR T-cell therapy (STR-P004) to induce remission in patients with autoimmune diseases (AID). (ASCO 2026) - P=N/A | "STARNA's STR-P004 utilizes a proprietary LNP platform to deliver anti-CD19 CAR mRNA intravenously, generating functional CAR-T cells directly in vivo, thereby improving accessibility. STR-P004, an off-the-shelf, repeatable therapy, demonstrated favorable safety and initial efficacy in AID, particularly for patients requiring continuous immunosuppression."

CAR T-Cell Therapy • IO biomarker • Preclinical • Alopecia • Glomerulonephritis • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • CD8 • IL6

Combined treatment of TROP‑2 targeted CAR-T and vascular disruptor CBP enhances anti‑tumor activity in triple‑negative breast cancer. (PubMed, Transl Oncol) - "Our findings demonstrated the potential of TROP-2 as a viable target for CAR-T therapy in breast cancer. The combination of TROP-2 CAR-T cells with CBP not only enhances the therapeutic efficacy but also maintains a favorable safety profile, offering a promising new strategy for the treatment of breast cancer."

IO biomarker • Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • TACSTD2

IN VIVO CD19 CAR-T CELL THERAPY (STR-P004) INDUCES REMISSION IN PATIENTS WITH AUTOIMMUNE DISEASES. (EHA 2026) - "STARNA's STR-P004 utilizes a proprietary LNP platform to deliver anti-CD19 CAR mRNA intravenously, generating functional CART cells directly in vivo, thereby improving accessibility.Aims: To develop and validate a targeted LNP-based,CD19-directed in vivo CART therapy for AID.STR-P004 integrates optimized mRNA into tissue and cell-selective LNPs.Its formulation contains a lead ionizable lipid,conjugated with a CD8-targeting ligand and anti-CD19 CAR mRNA.Adult AID patients received up to 8 doses via a TITE-BOIN12 design across three levels: de-escalation (0.03 mg/kg), starting (0.05 mg/kg), and DL2 (0.1 mg/kg), with systematic safety and efficacy evaluation.Preclinically,STR-P004 induced efficient CAR expression on CD8?T cells, enabling deep B-cell depletion and prolonged survival.In non-human primates, it showed a favorable safety profile with only transient liver enzyme elevations and cytokine release.No anti-PEG antibodies were detected.Between September1,2025,and..."

CAR T-Cell Therapy • IO biomarker • Preclinical • Alopecia • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Lupus • Renal Disease • CD8 • IL6

Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent-programmed CAR T cells. (PubMed, Sci Adv) - "Our study highlights the potent antitumor activity of low-dose decitabine-primed CAR T (dCAR T) cells in solid tumor models, a benefit previously confirmed in hematologic malignancies. This, in turn, stimulated endogenous CD8+ T cells, enhancing their antigen-spreading capacity and aiding in the clearance of abscopal antigen-negative tumors. These findings reveal the robust antigen-spreading capability of dCAR T cells, underscoring their clinical potential in addressing solid tumors with inherent antigen heterogeneity."

Heterogeneity • Journal • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor • CD8 • IFNG

Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial. (PubMed, Nat Commun) - P1/2 | "Previously, we showed that ex vivo priming with decitabine (DAC) enhances CAR T persistence and efficacy. Single-cell sequencing indicates that DAC priming enriches for memory-like progenitors, which maintain cytotoxic and memory signatures, and upregulates genes associated with T cell fitness and engagement of endogenous immunity. These data establish DAC-priming as a clinically feasible epigenetic reprogramming strategy enhanceing CAR T durability and efficacy, offering a generalizable paradigm for engineered cell therapies in malignant tumors."

Journal • P1/2 data • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • CD20

DUSP6 ablation restores CAR T-cell fitness impaired by tumor CD58 loss through invigoration of AP-1 signaling. (PubMed, Signal Transduct Target Ther) - "Here, we revealed that AP-1-mediated activation was attenuated in CAR T cells impaired by tumor CD58 loss, driving a decrease in mitochondrial biogenesis, metabolic kinetic impairment, mitochondrial membrane potential loss and ROS accumulation...Our findings repositioned CD58 not merely as an immune synapse component but also a metabolic checkpoint in CAR T-cell biology, the loss of which triggers AP-1-dependent mitochondrial derangement and creates a permissive landscape for intrinsic apoptosis, which can be ameliorated by ablation of the inhibitory phosphatase DUSP6. Crucially, DUSP6 ablation represents a promising engineering target to potentiate CAR T-cell efficacy in broader applications."

Journal • Metabolic Disorders • Oncology • CD58 • DUSP6

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with Philadelphia chromosome-positive b-ALL: Insights from real-world data (ASH 2025) - P | "Prior therapies included hematopoietic stem cell transplantation (HSCT) (24.1%), inotuzumab ozogamicin (14.8%), and blinatumomab (24.1%)...The median infusion dose was 0.60 (range: 0.44–1.00) × 10 8 viable CAR-T cells, with 88.9% of patients receiving bridge therapy...All patients recovered without sequelae: 9 received corticosteroids, and 11 received tocilizumab. Conclusion Real-world data demonstrate that Inati-cel exhibits excellent efficacy in patients with Ph+ B-ALL, yielding low toxicity, short treatment cycles, high complete molecular response rates, and favorable long-term survival. Extended follow-up could illuminate the long-term outcomes of Inati-cel use."

Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Central Nervous System Leukemia • Hematological Malignancies • Leukemia • ABL1 • IKZF1

Efficacy and safety profile of inaticabtagene autoleucel in Chinese adult patients with B-cell acute lymphoblastic leukemia who relapsed after their transplant: Insights from real-world data (ASH 2025) - P | "The median infusion dose was 0.60 (range: 0.42–1.00) × 10 8 viable CAR-T cells...Patients with and without prior blinatumomab exposure had similar OS (p = 0.62) and RFS (p = 0.58); the same was true for prior inotuzumab ozogamicin exposure (p = 0.86 and p = 0.67, respectively)...Conclusion Real-world data demonstrate that Inati-cel exhibits excellent efficacy in patients with B-ALL who relapse after HSCT and in patients with active extramedullary disease; its safety was also established. Extended follow-up is warranted to fully characterize the long-term outcomes of Inati-cel use."

Clinical • IO biomarker • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Central Nervous System Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Transplantation • IKZF1 • TP53

Novel bispecific epitope anti-CD5 nanobody CAR-T cells for refractory or relapsed T-cell malignancies (ASH 2025) - P1/2 | "We optimized the novel bispecific epitope anti-CD5 nanobody CAR construct, and showssuperior cytotoxic activity comparing with CD5 CAR (IASO Biotech) in vitro. We also got preliminary safetyand efficacy profiles in r/r T-cell lymphoma. This clinical trial is still ongoing, and long-term efficacy andclinical complication of CD5 CAR-T cell therapy still require further investigation."

CAR T-Cell Therapy • IO biomarker • Cutaneous T-cell Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoblastic Lymphoma • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Acute Lymphoblastic Leukemia • T Cell Non-Hodgkin Lymphoma • TERC

Enhanced efficacy and safety of optimized tandem CD19/CD20 CAR T-cell Therapy in refractory/relapsed B-cell lymphoma (ASH 2025) - P1 | "While tandem CD19/CD20 CAR-T cells show promise, we observed limitations in thefunctionality and persistence of a second-generation construct (CAR2019)...Common grade ≥3 adverseevents within 1 month were neutropenia (100%), thrombocytopenia (62%), and infection (25%).CAR2019(AS) exhibited robust expansion (median peak: 48486.9 copies/μg gDNA on day 10).ConclusionsOur novel incorporation of protease cleavage sites (AS) significantly enhances tandem CD19/CD20 CAR-Tfunctionality and exhaustion resistance. CAR2019(AS) achieves exceptional clinical efficacy with promisingsurvival in r/r BCL, establishing a potent dual-targeting strategy to overcome CD19 monotherapylimitations."

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • CD20

Safety and preliminary efficacy of a novel loop-optimized, BCMA/CD19 bispecific CAR-T therapy for refractory or relapsed autoimmune diseases patients (ASH 2025) - P1/2 | "Their persistent killing capacity against CD19+ or BCMA+ targets was comparable to that of singleCD19 or BCMA CAR-T cells. Novel Loop dual CD19/BCMA CAR-T demonstrated favorable efficacy and safety inrelapsed/refractory autoimmune diseases and new clinical trial is ongoing (NCT06947460)."

Clinical • IO biomarker • Cardiovascular • Fibrosis • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Interstitial Lung Disease • Lupus • Lupus Nephritis • Nephrology • Pneumonia • Pulmonary Arterial Hypertension • Pulmonary Disease • Renal Disease • Respiratory Diseases • Rheumatology • Scleroderma • Sjogren's Syndrome • Systemic Lupus Erythematosus • Systemic Sclerosis

Intrinsic NPRL2 and NPRL3 regulate the sensitivity of B-cell malignancies to CAR-T cell therapy. (PubMed, J Genet Genomics) - P1/2 | "Mechanistically, NPRL2/NPRL3 suppresses mTORC1 activity within tumor cells, negatively regulating the conjugation between tumor cells and CAR-T cells, consequently impairing CAR-T cell activation and cytotoxic function, ultimately facilitating immune escape. As therapeutic strategies, either genetic ablation of tumor-intrinsic NPRL2/NPRL3 or pharmacological activation of mTORC1 enhances CAR-T cell activation, cytotoxic degranulation, and tumor clearance both in vitro and in vivo. In conclusion, targeting tumor NPRL2/NPRL3 or directly activating mTOR represents a promising combinational strategy to potentiate CAR-T efficacy and overcome resistance in clinical practice."

IO biomarker • Journal • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients (ASH 2023) - "Correspondence to Drs. Zongcheng Li, Bing Liu, Lilin Ye, Yu Lan and Liang Huang."

CAR T-Cell Therapy • Clinical • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • GZMB • GZMH • GZMK • VPREB1

Changes in Glycosylation on the Cell Surface Result in Highly Potent and Long-Lasting Allogeneic CAR-T Therapy in Patients (ASH 2024) - "Thereby, it not only combats host rejection but also improves the potency of allo-CAR T cells...Following lymphodepletion of fludarabine (30-50 mg/m2/d) and cyclophosphamide (500-1000 mg/m2/d) for a duration of 3 days, patients receive a single-dose infusion of ET-901 at escalating doses of 1*10e6/kg, 3*10e6/kg, and 10*10e6/kg...All patients demonstrated objective responses, with significant CAR-T cell expansion, confirming the engineered cells' long-term immune privilege and activity. This represents a significant step in making allogeneic CAR T-cell therapy more viable and effective."

Clinical • Anemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Oncology • Thrombocytopenia • B2M

Preclinical development and a case report of a nanobody-based CLDN18.2 CAR-T IMC002 with reduced on-target off-tumor toxicity. (PubMed, Mol Cancer Ther) - "The highest non-severely toxic dose was 5×108 CAR-T cells/kg. In the clinical case report, we present a case with unresectable advanced gastric cancer achieved pathological complete response 10 months after IMC002 infusion and no signs of recurrence were indicated in subsequent clinical and radiological follow-ups. IMC002 shows effectiveness and safety in CLDN18.2-positive gastric and pancreatic cancer and its favorable profiles support further clinical development."

Journal • Preclinical • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CLDN18

BC19IGG4: Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease (clinicaltrials.gov) - P2 | N=9 | Not yet recruiting | Sponsor: Chinese PLA General Hospital

IO biomarker • New P2 trial • Immunology • Inflammation

BC19IGG4: Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease (clinicaltrials.gov) - P2 | N=9 | Recruiting | Sponsor: Chinese PLA General Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • IO biomarker • Immunology • Inflammation

Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy. (PubMed, Cell) - P1/2 | "In a phase I clinical trial, SPPL3-null, T cell receptor (TCR)-deficient anti-CD19 allogeneic CAR-T cells reached the safety primary endpoint, with grade 3 or higher cytokine release syndrome (CRS) observed in 3 out of 9 patients with relapsed/refractory B cell non-Hodgkin lymphoma (B-NHL) (ClinicalTrials.gov: NCT06014073). We therefore evaluated the safety of SPPL3-null, TCR-sufficient CAR-T therapy on three patients with lymphoma or leukemia for compassionate care and observed no clinical signs of graft-versus-host disease. Our findings suggest glycan shielding by SPPL3 deletion is a promising direction for optimizing universal CAR-T therapies."

Journal • B Cell Non-Hodgkin Lymphoma • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology